{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T17:39:14Z","timestamp":1770745154843,"version":"3.49.0"},"reference-count":76,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T00:00:00Z","timestamp":1426464000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0121664","type":"journal-article","created":{"date-parts":[[2015,3,16]],"date-time":"2015-03-16T18:18:52Z","timestamp":1426529932000},"page":"e0121664","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Endothelin A Receptor Antagonist, Atrasentan, Attenuates Renal and Cardiac Dysfunction in Dahl Salt-Hypertensive Rats in a Blood Pressure Independent Manner"],"prefix":"10.1371","volume":"10","author":[{"given":"Mohammed A.","family":"Samad","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ui Kyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joshua J.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingen","family":"Ke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter M.","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2015,3,16]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"e60008","DOI":"10.1371\/journal.pone.0060008","article-title":"Framingham risk score with cardiovascular events in chronic kidney disease","volume":"8","author":"SC Chen","year":"2013","journal-title":"PLoS One"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(05)17789-7","article-title":"Chronic kidney disease: the global challenge","volume":"365","author":"A Meguid El Nahas","year":"2005","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"AS Go","year":"2004","journal-title":"N Engl J Med"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1097\/01.ASN.0000123691.46138.E2","article-title":"Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies","volume":"15","author":"DE Weiner","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1093\/ndt\/11.7.1277","article-title":"Outcome and risk factors for left ventricular disorders in chronic uraemia","volume":"11","author":"PS Parfrey","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/ki.1989.192","article-title":"Impact of left ventricular hypertrophy on survival in end-stage renal disease","volume":"36","author":"JS Silberberg","year":"1989","journal-title":"Kidney Int"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"D de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1161\/01.HYP.0000102971.85504.7c","article-title":"Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention","volume":"42","author":"MJ Sarnak","year":"2003","journal-title":"Hypertension"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1001\/jama.286.4.421","article-title":"Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals","volume":"286","author":"HC Gerstein","year":"2001","journal-title":"JAMA"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1161\/01.CIR.0000139860.33974.28","article-title":"Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy","volume":"110","author":"D de Zeeuw","year":"2004","journal-title":"Circulation"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1161\/01.HYP.0000154082.72286.2a","article-title":"Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: losartan intervention for endpoint reduction in hypertension study","volume":"45","author":"H Ibsen","year":"2005","journal-title":"Hypertension"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"244","DOI":"10.7326\/0003-4819-139-4-200308190-00006","article-title":"Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis","volume":"139","author":"TH Jafar","year":"2003","journal-title":"Ann Intern Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators","volume":"342","author":"S Yusuf","year":"2000","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1681\/ASN.2007090970","article-title":"Role of remission clinics in the longitudinal treatment of CKD","volume":"19","author":"P Ruggenenti","year":"2008","journal-title":"J Am Soc Nephrol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"F1448","DOI":"10.1152\/ajprenal.00340.2009","article-title":"Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes","volume":"297","author":"E Gagliardini","year":"2009","journal-title":"Am J Physiol Renal Physiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa0708379","article-title":"Aliskiren combined with losartan in type 2 diabetes and nephropathy","volume":"358","author":"HH Parving","year":"2008","journal-title":"N Engl J Med"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.amjhyper.2004.06.029","article-title":"Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease","volume":"18","author":"A Sato","year":"2005","journal-title":"Am J Hypertens"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1073\/pnas.86.8.2863","article-title":"The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes","volume":"86","author":"A Inoue","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/332411a0","article-title":"A novel potent vasoconstrictor peptide produced by vascular endothelial cells","volume":"332","author":"M Yanagisawa","year":"1988","journal-title":"Nature"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2174\/157489006775244263","article-title":"The vascular endothelin system in hypertension\u2014recent patents and discoveries","volume":"1","author":"MM Hynynen","year":"2006","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"ref21","first-page":"179","article-title":"Endothelin: a mediator of renal disease progression","volume":"10","author":"I Bruzzi","year":"1997","journal-title":"J Nephrol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1681\/ASN.2010080869","article-title":"Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy","volume":"22","author":"DE Kohan","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"16810","DOI":"10.1073\/pnas.0611202104","article-title":"Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals","volume":"104","author":"N Bodyak","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1093\/cvr\/cvr133","article-title":"Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats","volume":"91","author":"S Bae","year":"2011","journal-title":"Cardiovasc Res"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0022-3565(25)12297-0","article-title":"Pharmacological characterization of A-127722: an orally active and highly potent ETA-selective receptor antagonist","volume":"276","author":"TJ Opgenorth","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s00125-010-2021-4","article-title":"Endothelin receptor A-specific stimulation of glomerular inflammation and injury in a streptozotocin-induced rat model of diabetes","volume":"54","author":"MA Saleh","year":"2011","journal-title":"Diabetologia"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"H72","DOI":"10.1152\/ajpheart.00556.2003","article-title":"Alterations in apoptosis regulatory factors during hypertrophy and heart failure","volume":"287","author":"PM Kang","year":"2004","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1161\/01.RES.87.2.118","article-title":"Morphological and molecular characterization of adult cardiomyocyte apoptosis during hypoxia and reoxygenation","volume":"87","author":"PM Kang","year":"2000","journal-title":"Circ Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1152\/japplphysiol.01506.2012","article-title":"Vitamin D signaling pathway plays an important role in the development of heart failure after myocardial infarction","volume":"114","author":"S Bae","year":"2013","journal-title":"J Appl Physiol (1985)"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1161\/HYPERTENSIONAHA.112.199240","article-title":"Genetic variants in Arhgef11 are associated with kidney injury in the Dahl salt-sensitive rat","volume":"60","author":"JM Williams","year":"2012","journal-title":"Hypertension"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1161\/01.HYP.0000222003.28517.99","article-title":"Podocyte injury underlies the glomerulopathy of Dahl salt-hypertensive rats and is reversed by aldosterone blocker","volume":"47","author":"M Nagase","year":"2006","journal-title":"Hypertension"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"2184","DOI":"10.1161\/01.CIR.0000094397.19932.78","article-title":"Endothelin receptor blockers in cardiovascular disease","volume":"108","author":"S Rich","year":"2003","journal-title":"Circulation"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"62S","DOI":"10.1016\/j.jacc.2004.02.042","article-title":"Endothelin receptor antagonists in pulmonary arterial hypertension","volume":"43","author":"RN Channick","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1161\/01.CIR.99.14.1802","article-title":"Functional effects of endothelin and regulation of endothelin receptors in isolated human nonfailing and failing myocardium","volume":"99","author":"B Pieske","year":"1999","journal-title":"Circulation"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1007\/s00395-010-0094-3","article-title":"Chronic acetaminophen attenuates age-associated increases in cardiac ROS and apoptosis in the Fischer Brown Norway rat","volume":"105","author":"SK Kakarla","year":"2010","journal-title":"Basic Res Cardiol"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1161\/01.CIR.0000153351.86708.F7","article-title":"Different contributions of endothelin-A and endothelin-B receptors in postischemic cardiac dysfunction and norepinephrine overflow in rat hearts","volume":"111","author":"S Yamamoto","year":"2005","journal-title":"Circulation"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1161\/01.CIR.85.2.504","article-title":"Plasma endothelin correlates with the extent of pulmonary hypertension in patients with chronic congestive heart failure","volume":"85","author":"RJ Cody","year":"1992","journal-title":"Circulation"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1093\/oxfordjournals.ndt.a027833","article-title":"Endothelin and cardiovascular remodelling in end-stage renal disease","volume":"13","author":"K Demuth","year":"1998","journal-title":"Nephrol Dial Transplant"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1161\/01.HYP.36.1.62","article-title":"Hypertension in black patients: an emerging role of the endothelin system in salt-sensitive hypertension","volume":"36","author":"A Ergul","year":"2000","journal-title":"Hypertension"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1161\/01.HYP.0000072982.70666.E8","article-title":"Effects of endothelin-1 and endothelin-1 receptor blockade on cardiac output, aortic pressure, and pulse wave velocity in humans","volume":"41","author":"TJ Vuurmans","year":"2003","journal-title":"Hypertension"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/0014-5793(91)80007-P","article-title":"Cloning and expression of human endothelin-1 receptor cDNA","volume":"287","author":"K Hosoda","year":"1991","journal-title":"FEBS Lett"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/FJC.0b013e3181e89f36","article-title":"Inhibition of endothelin-1 and hypoxia-induced pulmonary pressor responses in the rat by a novel selective endothelin-A receptor antagonist, di-n-butylaminocarbamyl-L-leucyl-D-tryptophanyl-D-4-chloro-Phe","volume":"56","author":"LD Yan","year":"2010","journal-title":"J Cardiovasc Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1161\/HYPERTENSIONAHA.108.113068","article-title":"Efficacy and safety of atrasentan in patients with cardiovascular risk and early atherosclerosis","volume":"52","author":"E Raichlin","year":"2008","journal-title":"Hypertension"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"3394","DOI":"10.1681\/ASN.2006060635","article-title":"Endothelin-a receptor blockade improves renal microvascular architecture and function in experimental hypercholesterolemia","volume":"17","author":"AR Chade","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1093\/jmcb\/mjs002","article-title":"Cardiac-specific knockout of ET(A) receptor mitigates low ambient temperature-induced cardiac hypertrophy and contractile dysfunction","volume":"4","author":"Y Zhang","year":"2012","journal-title":"J Mol Cell Biol"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/ki.2014.143","article-title":"Endothelin and endothelin antagonists in chronic kidney disease","volume":"86","author":"DE Kohan","year":"2014","journal-title":"Kidney Int"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1681\/ASN.2014020174","article-title":"Endothelin antagonists in diabetic nephropathy: back to basics","volume":"25","author":"K Chandrashekar","year":"2014","journal-title":"J Am Soc Nephrol"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"112S","DOI":"10.1042\/CS103S112S","article-title":"Pharmacology of endothelin receptor antagonists ABT-627, ABT-546, A-182086 and A-192621: ex vivo and in vivo studies","volume":"103","author":"JL Wessale","year":"2002","journal-title":"Clin Sci (Lond)"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1006\/jmcc.2002.2075","article-title":"Local cardiac renin-angiotensin system: hypertension and cardiac failure","volume":"34","author":"J Varagic","year":"2002","journal-title":"J Mol Cell Cardiol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"105316","DOI":"10.1155\/2012\/105316","article-title":"The Relationship between Reactive Oxygen Species and Cardiac Fibrosis in the Dahl Salt-Sensitive Rat under ACEI Administration","volume":"2012","author":"R Tanaka","year":"2012","journal-title":"Vet Med Int"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1139\/y04-005","article-title":"Angiotensin-converting enzyme inhibitor captopril prevents volume overload cardiomyopathy in experimental chronic aortic valve regurgitation","volume":"82","author":"E Plante","year":"2004","journal-title":"Can J Physiol Pharmacol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1080\/10715760902801517","article-title":"Cardiac mitochondrial function and tissue remodelling are improved by a non-antihypertensive dose of enalapril in spontaneously hypertensive rats","volume":"43","author":"B Piotrkowski","year":"2009","journal-title":"Free Radic Res"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1097\/00004872-198310000-00009","article-title":"Cardiac regression and blood pressure control in the Dahl rat treated with either enalapril maleate (MK 421, an angiotensin converting enzyme inhibitor) or hydrochlorothiazide","volume":"1","author":"JN Sharma","year":"1983","journal-title":"J Hypertens"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/pmic.201000018","article-title":"Endothelin-1- and isoproterenol-induced differential protein expression and signaling pathway in HL-1 cardiomyocytes","volume":"11","author":"HM Hong","year":"2011","journal-title":"Proteomics"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/S0022-2828(03)00153-6","article-title":"An overview of endothelin signaling in the cardiac myocyte","volume":"35","author":"PH Sugden","year":"2003","journal-title":"J Mol Cell Cardiol"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1038\/ncpneph0891","article-title":"Reversal of proteinuric renal disease and the emerging role of endothelin","volume":"4","author":"M Barton","year":"2008","journal-title":"Nat Clin Pract Nephrol"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/ki.2011.380","article-title":"Treatment of chronic kidney disease","volume":"81","author":"JM Turner","year":"2012","journal-title":"Kidney Int"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1111\/j.1745-7254.2006.00447.x","article-title":"Effects of endothelin ETA receptor blocker LU 135252 on cardiac remodeling and survival in a hypertensive rat model of chronic heart failure","volume":"27","author":"QG Xia","year":"2006","journal-title":"Acta Pharmacol Sin"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/sj.bjp.0706384","article-title":"Reversal of cardiac dysfunction by selective ET-A receptor antagonism","volume":"146","author":"A Allan","year":"2005","journal-title":"Br J Pharmacol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1161\/hy0202.103481","article-title":"Fibrosis, matrix metalloproteinases, and inflammation in the heart of DOCA-salt hypertensive rats: role of ET(A) receptors","volume":"39","author":"FZ Ammarguellat","year":"2002","journal-title":"Hypertension"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1161\/01.HYP.0000117296.30296.14","article-title":"ETA receptor mediates altered leukocyte-endothelial cell interaction and adhesion molecules expression in DOCA-salt rats","volume":"43","author":"GE Callera","year":"2004","journal-title":"Hypertension"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1161\/01.CIR.102.19.2434","article-title":"Endothelins and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs","volume":"102","author":"TF Luscher","year":"2000","journal-title":"Circulation"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.bbadis.2010.03.012","article-title":"Therapeutic potential of endothelin receptor antagonists for chronic proteinuric renal disease in humans","volume":"1802","author":"M Barton","year":"2010","journal-title":"Biochim Biophys Acta"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1161\/HYPERTENSIONAHA.109.132670","article-title":"Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease","volume":"54","author":"N Dhaun","year":"2009","journal-title":"Hypertension"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1146\/annurev.pharmtox.41.1.851","article-title":"Endothelin system: the double-edged sword in health and disease","volume":"41","author":"RM Kedzierski","year":"2001","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"DL Andress","year":"2012","journal-title":"Life Sci"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S2213-8587(13)70029-9","article-title":"Effect on blood pressure of combined inhibition of endothelin-converting enzyme and neutral endopeptidase with daglutril in patients with type 2 diabetes who have albuminuria: a randomised, crossover, double-blind, placebo-controlled trial","volume":"1","author":"A Parvanova","year":"2013","journal-title":"Lancet Diabetes Endocrinol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1681\/ASN.2008050482","article-title":"Avosentan reduces albumin excretion in diabetics with macroalbuminuria","volume":"20","author":"RR Wenzel","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"HL Hillege","year":"2002","journal-title":"Circulation"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.lfs.2012.01.011","article-title":"Clinical efficacy of the selective endothelin A receptor antagonist, atrasentan, in patients with diabetes and chronic kidney disease (CKD)","volume":"91","author":"DL Andress","year":"2012","journal-title":"Life Sci"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1097\/00004872-200409000-00024","article-title":"Fasudil, a Rho-kinase inhibitor, attenuates glomerulosclerosis in Dahl salt-sensitive rats","volume":"22","author":"T Nishikimi","year":"2004","journal-title":"J Hypertens"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1097\/00004872-200306000-00012","article-title":"Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats","volume":"21","author":"M Yu","year":"2003","journal-title":"J Hypertens"},{"key":"ref73","first-page":"99","article-title":"Comparative effects of an angiotensin-converting enzyme inhibitor and an angiotensin II antagonist in Dahl rats","volume":"5","author":"M Ideishi","year":"1994","journal-title":"Blood Press Suppl"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1161\/01.HYP.0000049881.25304.73","article-title":"Renoprotection by ACE inhibition or aldosterone blockade is blood pressure-dependent","volume":"41","author":"KA Griffin","year":"2003","journal-title":"Hypertension"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1038\/ki.2013.477","article-title":"Disparate effects of single endothelin-A and-B receptor blocker therapy on the progression of renal injury in advanced renovascular disease","volume":"85","author":"AR Chade","year":"2014","journal-title":"Kidney Int"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"F218","DOI":"10.1152\/ajprenal.00089.2011","article-title":"Endothelin-A receptor blockade slows the progression of renal injury in experimental renovascular disease","volume":"301","author":"S Kelsen","year":"2011","journal-title":"Am J Physiol Renal Physiol"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0121664","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T00:48:00Z","timestamp":1747788480000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0121664"}},"subtitle":[],"editor":[{"given":"Nanette H","family":"Bishopric","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2015,3,16]]},"references-count":76,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2015,3,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0121664","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3,16]]}}}